Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amerise Biosciences Ltd (formerly Amradeep Industries, BSE: 531681) submitted its 40th Annual Report for FY 2024-25 along with the notice for its AGM to be held on 23rd September 2025 in Ahmedabad. The company reported no revenue from operations during the year and said it had no significant business activity, but managed a token net profit of Rs. 56,831 from other income. No dividend was recommended given accumulated losses, and share capital remained unchanged at Rs. 66.07 lakh (66.07 lakh equity shares of Rs. 1 each). Shareholders will vote on re-appointment of director Dineshkumar Rathod, re-appointment of statutory auditor M/s. Bipin & Co. for a 5-year term till 2030, appointment of Kelash Bunkar as Independent Director, and two special resolutions to raise the borrowing cap and investment/loan/guarantee limits to Rs. 100 crore each under Sections 180(1)(c) and 186 of the Companies Act.
Routine compliance filing with AGM notice, but the underlying picture is weak: zero operational revenue, negligible profit, and no business activity in the year. The two special resolutions seeking Rs. 100 crore headroom for borrowings and investments hint at possible future fundraising or expansion plans, which shareholders should weigh against the company's currently dormant operations.